Platinum-doublet chemotherapy followed by large-fraction radiotherapy with tislelizumab for advanced non-squamous NSCLC

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 2, single-center interventional protocol for patients with stage IIIB/C–IV non-squamous NSCLC. Participants receive platinum-based doublet chemotherapy, then undergo hypofractionated (large-fraction/SBRT-like) radiotherapy combined with tislelizumab, followed by continued tislelizumab maintenance. The study enrolls adults with ECOG 0–2 and excludes tumors with actionable driver mutations (EGFR, ALK, BRAF, ROS1, RET, MET, etc.). The primary focus is on observing tumor response, safety, and tolerability of this sequential chemo–radiation–immunotherapy approach.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age 18-75 years old, gender is not limited;
2. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
3. Patients with stage IIIB/C-IV non-squamous non-small cell lung cancer confirmed by cytology or histology;
4. Tumor histology or hematology confirms no EGFR mutations and no mutations or positive driver genes for ALK, BRAF, ROS1, RET, MET, etc or Targeted drug therapy leads to drug resistance progression

Exclusion Criteria:

1. Patients with uncontrolled autoimmune diseases;
2. Patients who have experienced autoimmune reactions within the past 6 months and whose conditions have not improved or are unstable after corresponding treatments, such as pneumonia, thyroiditis, myocarditis, etc. that have not stabilized after treatment;
3. Patients who have previously received systemic chemotherapy, or adjuvant or neoadjuvant therapy, and the time from the last treatment to recurrence is less than 3 months;
4. Patients with known allergies or contraindications to the study drug or its excipients;
5. Pregnant or lactating female patients, or female patients of childbearing potential with a positive baseline pregnancy test;
6. Female patients of childbearing potential or male patients with reproductive plans who are unwilling to use effective contraception during the entire trial period and for 6 months after the end of the trial;
7. Patients whose comorbidities or other conditions may affect compliance with the protocol or are deemed unsuitable for participation in this study by the investigator.

Where it's running

• Zibo Municipal Hospital
  Zibo, Shandong, China Recruiting

Study contacts

• Study coordinator: Qiang Wang
• Email: 18953316759@163.com
• Phone: +8618953316759

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Tislelizumab with platinum-doublet chemotherapy followed by hypofractionated radiotherapy for stage IIIB/C–IV non-squamous NSCLC

  This trial tests whether adding Tislelizumab to platinum-doublet chemotherapy followed by hypofractionated radiotherapy can help people with stage IIIB/C–IV non‑squamous non‑small cell lung cancer who have not had prior systemic therapy.

  Recruiting Phase 2 Zibo Municipal Hospital · Zibo, Shandong · NCT07085182

• Intestinal Low-Dose Radiotherapy plus Immunochemotherapy to Convert Borderline Resectable or Unresectable Esophageal Squamous Cell Carcinoma

  This study tests whether adding a very low dose intestinal radiotherapy with immunochemotherapy can make advanced esophageal squamous cell carcinoma operable for patients who can’t be surgically removed today.

  Recruiting Phase 2 Shantou University Medical College · Shantou, Guangdong · NCT07339488

• Tislelizumab with Anlotinib and Nab-Paclitaxel before surgery for resectable NSCLC

  A group of adults with stage II–III non-small cell lung cancer is given tislelizumab plus anlotinib and nab-paclitaxel before surgery to see if the treatment helps shrink tumors and is safe.

  Recruiting Phase 2 Qilu Hospital of Shandong University · Jinan, Shandong · NCT07089199

• Adding tislelizumab with or without the probiotic Probio-M9 to pre-surgery chemoradiation for pMMR/MSS locally advanced rectal cancer.

  This will see if adding the PD-1 drug tislelizumab, with or without the probiotic Probio-M9, to standard pre-surgery chemoradiation helps adults with pMMR/MSS locally advanced rectal cancer.

  Recruiting Phase 2 Seventh Medical Center of PLA General Hospital · Beijing, Beijing Municipality · NCT07458529

• Adjuvant L-TIL plus tislelizumab after surgery for resectable NSCLC without pCR

  This trial tests whether giving liquid tumor-infiltrating lymphocytes (L-TIL) together with the PD-1 blocker tislelizumab after surgery helps people with resectable stage II–IIIB NSCLC who did not achieve a complete response to pre-surgery chemoimmunotherapy.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07330037

• Nephron-sparing tislelizumab and nab-paclitaxel for renal pelvic cancer

  This study will try combining tislelizumab and nab‑paclitaxel to shrink HER‑2–expressing renal pelvic tumors in adults eligible for ureteroscopic laser ablation.

  Recruiting Phase 2 Tianjin Medical University Second Hospital · Tianjin, Outside U.S. · NCT07233252

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.